CNBX Pharmaceuticals Inc.
CNBX
$0.00
$0.000.00%
OTC PK
| 02/28/2026 | 11/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.06% | -50.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.06% | -50.66% | |||
| Operating Income | -14.06% | 50.66% | |||
| Income Before Tax | 61.21% | 24.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 61.21% | 24.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 61.21% | 24.25% | |||
| EBIT | -14.06% | 50.66% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 100.00% | 66.67% | |||
| Normalized Basic EPS | 100.00% | 75.00% | |||
| EPS Diluted | 100.00% | 66.67% | |||
| Normalized Diluted EPS | 100.00% | 75.00% | |||
| Average Basic Shares Outstanding | 27.04% | 186.08% | |||
| Average Diluted Shares Outstanding | 27.04% | 186.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||